Before mediation, the patient was diagnosed with prostate malignant tumor, with the value of tumor marker prostate-specific antigen up to 100 or more. Then, the patient received the combination drug therapy of CHA for injection and anti-prostate cancer drugs. During 1 year and 7 months of mediation, the prostate-specific antigen gradually decreased to 22.59, and the patient’s quality of life was improved. The patient died of COVID-19 in January, 2022.